8B2U

Crystal structure of SUDV VP40 in complex with salicylic acid


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.80 Å
  • R-Value Free: 0.230 
  • R-Value Work: 0.208 
  • R-Value Observed: 0.209 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.4 of the entry. See complete history


Literature

Development of a Crystallographic Screening to Identify Sudan Virus VP40 Ligands.

Werner, A.D.Krapoth, N.Norris, M.J.Heine, A.Klebe, G.Saphire, E.O.Becker, S.

(2024) ACS Omega 9: 33193-33203

  • DOI: https://doi.org/10.1021/acsomega.4c04829
  • Primary Citation of Related Structures:  
    8B1S, 8B2U

  • PubMed Abstract: 

    The matrix protein VP40 of the highly pathogenic Sudan virus (genus Orthoebolavirus ) is a multifunctional protein responsible for the recruitment of viral nucleocapsids to the plasma membrane and the budding of infectious virions. In addition to its role in assembly, VP40 also downregulates viral genome replication and transcription. VP40's existence in various homo-oligomeric states is presumed to underpin its diverse functional capabilities during the viral life cycle. Given the absence of licensed therapeutics targeting the Sudan virus, our study focused on inhibiting VP40 dimers, the structural precursors to critical higher-order oligomers, as a novel antiviral strategy. We have established a crystallographic screening pipeline for the identification of small-molecule fragments capable of binding to VP40. Dimeric VP40 of the Sudan virus was recombinantly expressed in bacteria, purified, crystallized, and soaked in a solution of 96 different preselected fragments. Salicylic acid was identified as a crystallographic hit with clear electron density in the pocket between the N- and the C-termini of the VP40 dimer. The binding interaction is predominantly coordinated by amino acid residues leucine 158 (L158) and arginine 214 (R214), which are key in stabilizing salicylic acid within the binding pocket. While salicylic acid displayed minimal impact on the functional aspects of VP40, we delved deeper into characterizing the druggability of the identified binding pocket. We analyzed the influence of residues L158 and R214 on the formation of virus-like particles and viral RNA synthesis. Site-directed mutagenesis of these residues to alanine markedly affected both VP40's budding activity and its effect on viral RNA synthesis, underscoring the potential of the salicylic acid binding pocket as a drug target. In summary, our findings lay the foundation for structure-guided drug design to provide lead compounds against Sudan virus VP40.


  • Organizational Affiliation

    Institute for Virology, University of Marburg, D-35043 Marburg, Hessen, Germany.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Matrix protein VP40297Sudan ebolavirusMutation(s): 0 
Gene Names: VP40DF49_53412gpVP40DH33_45403gpVP40SEBOVgp3
UniProt
Find proteins for Q5XX06 (Sudan ebolavirus (strain Human/Uganda/Gulu/2000))
Explore Q5XX06 
Go to UniProtKB:  Q5XX06
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ5XX06
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
SAL (Subject of Investigation/LOI)
Query on SAL

Download Ideal Coordinates CCD File 
B [auth A]2-HYDROXYBENZOIC ACID
C7 H6 O3
YGSDEFSMJLZEOE-UHFFFAOYSA-N
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.80 Å
  • R-Value Free: 0.230 
  • R-Value Work: 0.208 
  • R-Value Observed: 0.209 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 62.302α = 90
b = 90.622β = 94.022
c = 48.104γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
PHENIXrefinement
XDSdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
LOEWE Center DRUIDGermany--

Revision History  (Full details and data files)

  • Version 1.0: 2023-09-27
    Type: Initial release
  • Version 1.1: 2024-04-24
    Changes: Structure summary
  • Version 1.2: 2024-07-31
    Changes: Database references
  • Version 1.3: 2024-08-14
    Changes: Database references
  • Version 1.4: 2024-11-13
    Changes: Structure summary